Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas

Otology and Neurotology

Volumn 25, Issue 5, 2004, Pages 791-796

  O'Reilly, Brian F ^a   Kishore, Ameet ^a   Crowther, John A ^a   Smith, Colin ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Growth; Growth factor receptors; Vestibular schwannoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN;

CANCER INCIDENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GROWTH RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; TISSUE SECTION; TUMOR GROWTH; VESTIBULAR SCHWANNOMA;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 4544223227     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200409000-00024     Document Type: Review

References (28)

1. Tos M, Charabi S, Thomsen J. Acoustic neuroma/vestibular schwannoma, epidemiology, symptomatology, diagnosis, expectancy and surgical results. Eur Arch Otorhinolaryngol 1998;255:1-6.
2. Thomsen J, Tos M. Acoustic neuroma: clinical aspects, audiovestibular assessment, diagnostic delay, and growth rate. Am J Otol 1990;11:12-9.
3. O'Reilly B, Murray CD, Hadley DM. The conservative management of acoustic neuroma: a review of forty-four patients with magnetic resonance imaging. Clin Otolaryngol Allied Sci 2000;25:93-7.
4. Charabi S, Tos M, Thomsen J, et al. Vestibular schwannoma growth: the continuing controversy. Laryngoscope 2000;110:1720-5.
5. Valvassori GE, Guzman M. Growth rate of acoustic neuromas. Am J Otol 1989;10:174-6.
6. Bederson JB, von Ammon KV, Wickmann WW. Conservative treatment of patients with acoustic tumors. Neurosurgery 1991;28:645-51.
7. Abaza MM, Makariou E, Armstrong M, et al. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 1996;106:694-9.
8. Kishore A, Crowther JA, O'Reilly BF. Our experience of vestibular schwannomas in type 2 neurofibromatosis: a 20 year review. Indian J Otol 2001;7:97-101.
9. Brown DC, Gatter KC. Ki 67 protein: the immaculate deception? Histopathology 2002;40:2-11.
10. Aguiar PH, Tatagiba M, Samii M, et al. The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1. Acta Neurochir 1995;134:40-5.
11. Morrissey TK, Levi AD, Nuijens A, et al. Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. Proc Natl Acad Sci USA 1995;92:1431-5.
12. Carroll SL, Miller ML, Frohnert PW, et al. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 1997;17:1642-59.
13. Tzeng SF, Deibler GE, DeVries GH. Myelin basic protein and myelin basic protein peptides induce the proliferation of Schwann cells via ganglioside GM1 and the FGF receptor. Neurochem Res 1999;24:255-60.
14. Nair SB, Leung HY, Ince P, et al. Fibroblast growth factor receptor expression in vestibular schwannomas. Clin Otolaryngol Allied Sci 2000;25:570-6.
15. Antinheimo J, Haapasalo H, Seppala M, et al. Proliferation potential of sporadic and neurofibromatosis 2 associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labelling. J Neuropathol Exp Neurol 1995;54:776-82.
16. Charabi S, Engel P, Charabi B, et al. Growth of vestibular schwannomas: in situ model employing the monoclonal antibody Ki-67 and DNA flow cytometry. Am J Otol 1996;17:301-6.
17. Lesser THJ, Janzer RC, Kleihues P, et al. Clinical growth rate of acoustic schwannomas: correlation with the growth fraction as defined by the monoclonal antibody Ki-67. Skull Base Surg 1991;1:11-5.
18. Szeremeta W, Monsell EM, Rock JP, et al. Proliferation indices of vestibular schwannomas by Ki-67 and proliferating cell nuclear antigen. Am J Otol 1995;16:616-9.
19. Weit RJ, Ruby SG, Bauer GP. Proliferating cell nuclear antigen in the determination of growth rates in acoustic neuromas. Am J Otol 1994;15:294-8.
20. Wennerberg J, Mercke U. Growth potential of acoustic neuromas. Am J Otol 1989;10:293-6.
21. Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 1995;113:179-80.
22. Tos M, Charabi S, Thomsen J. Incidence of vestibular schwannomas. Laryngoscope 1999;109:736-40.
23. Tos M. Thomsen J. Acoustic neuromas: diagnostic delay, growth rate and possible non surgical treatment. Acta Otolaryngol Suppl (Stockh) 1988;452:26-33.
24. Lanser MJ, Frazer K, Sussman SA. Epidemiology, pathogenesis and genetics of acoustic tumors. Otolaryngol Clin North Am 1992;25:499-520.
25. Lee KS, Nagashimo T, Cho KG, et al. The proliferating activity of neurilemmomas. Surg Neural 1989;32:427-33.
26. Gassmann M, Lemke G. Neuregulins and neuregulin receptors in neural development. Curr Opin Neurobiol 1997;7:87-92.
27. Sherman L, Sleeman JP, Hennigan RF, et al. Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro. Oncogene 1999;18:6692-9.
28. Rahmatullah M, Schroering A, Rothblum K, et al. Synergistic regulation of Schwann cell proliferation by heregulin and forskolin. Mol Cell Biol 1998;18:6245-52.